PACS (PACS) Q1 2026 Earnings Call Transcript

PACS Group delivered strong Q1 results with revenue of $1.42 billion, up 11% year over year, net income of $80.7 million versus $28.5 million, and adjusted EBITDA up 75% to $170 million. The company raised 2026 adjusted EBITDA guidance to $605 million-$625 million, reaffirmed revenue guidance of $5.5 billion-$5.75 billion, and approved a new $250 million share repurchase authorization. Operating trends were solid, with same-store revenue up 8%, occupancy at 90.9%, skilled mix up 90 bps to 30.5%, and liquidity of about $800 million with net leverage at just 0.1x.

Analysis

PACS is transitioning from a story of basic occupancy recovery to one of operating-system compounding: the real upside now comes from the conversion of newly acquired/ramping assets into mature cash-generating centers. That matters because the market usually underestimates how much EBITDA leverage sits in the last 10-15 points of occupancy and in skilled-mix normalization; those are not one-quarter effects, they typically persist for 4-8 quarters as referral relationships, staffing quality, and payer contracting reprice the asset.

The cleaner signal is the guidance architecture change. By stripping acquisition revenue from the outlook while still raising EBITDA, management is implicitly saying the base portfolio is now doing more of the work, which should compress perceived execution risk and raise the multiple on “organic” earnings. The secondary effect is that M&A becomes more valuable, not less: with a low-leverage balance sheet and buyback authorization, PACS has optionality to either recycle capital into distressed tuck-ins or repurchase stock if the public market continues to price the platform as a levered healthcare operator rather than a self-funded roll-up.

The key risk is that the market may over-extend the quality-and-reimbursement narrative. A meaningful portion of the quarter’s upside was aided by timing-sensitive incentive receipts, and the company is now more exposed to a gap between headline operating strength and cash conversion if state payments slip. On the other side, the ongoing control/investigation overhang is a longer-dated sentiment brake: even if it does not impair operations, it can cap multiple expansion until there is cleaner closure, likely a 3-12 month catalyst window rather than a days/weeks trade.

Net-net, this looks like a higher-quality compounding story than the headline earnings beat suggests, but the easiest money is probably in the next leg of re-rating if the next 1-2 quarters confirm same-store momentum without incremental subsidy noise. The setup favors a longs-only expression versus lower-quality healthcare names with more regulatory or labor sensitivity, and it also makes PACS a plausible source of capital to fund better-vetted peers if the stock runs ahead of fundamentals.

Key Decisions for Investors

• Long PACS into the next 1-2 quarters on confirmation that same-store occupancy and skilled mix stay on trend; target a 15-20% upside re-rating if organic EBITDA beats persist, but trim if the stock starts pricing in uninterrupted incentive receipts.
• Buy PACS Jan-2027 call spreads to express the re-rating thesis with defined downside; use a strike structure that monetizes a move on cleaner organic guidance and reduces exposure to timing noise from state payments.
• Pair trade: long PACS / short a weaker-skilled-nursing or post-acute operator with higher leverage and weaker occupancy traction over 3-6 months; the relative value is in PACS’s balance-sheet flexibility and better operating leverage.
• If PACS rallies hard on the buyback announcement, fade the first move with a short-dated hedge: the authorization is optional, not committed, so near-term multiple expansion can outrun actual repurchases.